Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Other Operating Expenses (2017 - 2025)

Historic Other Operating Expenses for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $2.5 million.

  • Aclaris Therapeutics' Other Operating Expenses fell 2054.24% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.6 million, marking a year-over-year increase of 322297.63%. This contributed to the annual value of $104.9 million for FY2024, which is 488826.48% up from last year.
  • Latest data reveals that Aclaris Therapeutics reported Other Operating Expenses of $2.5 million as of Q3 2025, which was down 2054.24% from $3.4 million recorded in Q2 2025.
  • Over the past 5 years, Aclaris Therapeutics' Other Operating Expenses peaked at $94.9 million during Q4 2024, and registered a low of -$13.2 million during Q4 2023.
  • In the last 5 years, Aclaris Therapeutics' Other Operating Expenses had a median value of $3.2 million in 2024 and averaged $8.2 million.
  • Within the past 5 years, the most significant YoY rise in Aclaris Therapeutics' Other Operating Expenses was 247555.56% (2023), while the steepest drop was 25373.81% (2023).
  • Over the past 5 years, Aclaris Therapeutics' Other Operating Expenses (Quarter) stood at $3.3 million in 2021, then skyrocketed by 157.21% to $8.6 million in 2022, then plummeted by 253.74% to -$13.2 million in 2023, then surged by 816.65% to $94.9 million in 2024, then tumbled by 97.31% to $2.5 million in 2025.
  • Its Other Operating Expenses was $2.5 million in Q3 2025, compared to $3.4 million in Q2 2025 and $1.8 million in Q1 2025.